References
Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL,
Montori VM, Schlechte JA and Wass JA. Diagnosis
and treatment of hyperprolactinemia: an Endocrine
Society clinical practice guideline. J. Clin. Endocrinol.
Metab. (2011) 96: 273-88.
Ignacak A, Kasztelnik M, Sliwa T, Korbut R, Rajda K
and Guzik T. Prolactin–not only lactotrophin. A “new”
view of the “old” hormone. J. Physiol. Pharmacol.
(2012) 63: 435-43.
Capozzi A, Scambia G, Pontecorvi A and Lello S.
Hyperprolactinemia: pathophysiology and therapeutic
approach. Gynecol. Endocrinol. (2015) 31: 506-10.
Pala NA, Laway BA, Misgar RA and Dar RA.
Metabolic abnormalities in patients with prolactinoma:
response to treatment with cabergoline. Diabetol.
Metab. Syndr. (2015) 7: 1.
Haring R, Friedrich N, Völzke H, Vasan RS, Felix
SB, Dörr M, zu Schwabedissen HEM, Nauck M
and Wallaschofski H. Positive association of
serum prolactin concentrations with all-cause and
cardiovascular mortality. Eur. Heart J. (2014) 35:
1215-21.
Tworoger SS, Sluss P and Hankinson SE. Association
between plasma prolactin concentrations and risk of
breast cancer among predominately premenopausal
women Cancer Res. (2006) 66: 2476-82.
Fernandez I, Touraine P and Goffin V. Prolactin and
human tumourogenesis. J. Neuroendocrinol. (2010)
22: 771-7.
Verhelst J and Abs R. Hyperprolactinemia. Treat
Endocrinol. (2003) 2: 23-32.
De Bellis A, Colao A, Pivonello R, Savoia A, Battaglia
M, Ruocco G, Tirelli G, Lombardi G, Bellastella A
and Bizzarro A. Antipituitary antibodies in idiopathic
hyperprolactinemic patients. Ann. N. Y. Acad. Sci.
(2007) 1107: 129-35.
Dekkers OM, Lagro J, Burman P, Jørgensen JO, Romijn
JA and Pereira AM. Recurrence of hyperprolactinemia
after withdrawal of dopamine agonists: systematic
review and meta-analysis. J. Clin. Endocrinol. Metab.
(2010) 95: 43-51.
Saadat N, Esmaily H, Abbasinazari M, Tohidi M,
Salamzadeh J, Hadaegh F, Tolabi M, Kalantar-Hormozi
M and Dibaj M. Does twice-weekly cabergoline
improve anthropometrical and biochemical profiles in
prediabetes? A randomized double-blind clinical trial
pilot study. Iran. J. Pharm. Res. (2015) 14: 77.
Coulter ID and Willis EM. The rise and rise of
complementary and alternative medicine: a sociological
perspective. Med. J. Aust. (2004) 180: 587-90.
Bahadori S, Salamzadeh J, Kamalinejad M, Ardekani
MRS, Keshavarz M and Ahmadzadeh A. Study of
the Effect of an Oral Formulation of Fig and Olive
on Rheumatoid Arthritis (RA) Remission Indicators:
A Randomized Clinical Trial. Iran. J. Pharm. Res.
(2016) 15: 537.
Sharaibi OJ, Ogundipe OT, Afolayan AJ and Aworinde
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
(12)
(13)
(14)
Kabiri M et al. / IJPR (2019), 18 (3): 1612-1621
1620
DO. Ethnobotanical survey and phytochemical
analysis of medicinal plants used for the treatment of
hyperprolactinemia in Lagos State, Nigeria. J. Med.
Plant Res. (2014) 8: 1284-8.
Hasani-Ranjbar S, Vahidi H, Taslimi S, Karimi N,
Larijani B and Abdollahi M. A systematic review on
the efficacy of herbal medicines in the management
of human drug-induced hyperprolactinemia; potential
sources for the development of novel drugs. Int. J.
Pharmacol. (2010) 6: 691-5.
Jones WP, Chin Y-W and Kinghorn AD. The role of
pharmacognosy in modern medicine and pharmacy.
Curr. Drug Targets (2006) 7: 247-64.
Ibn Sina. Al- Qanun fi al- tibb [The Canon of
Medicine]. Muhammad Amin al - Dinnawi (ed.) 2nd ed.
Dar al- Kotob Al- Ilmiyah Publisher, Beirut, Lebanon
(2009) 383-382.
Franke R and Schilcher H. Relevance And Use of
Chamomile (Matricaria Recutita L.). International
Society for Horticultural Science (ISHS); 2007,
Leuven, Belgium.
Srivastava JK, Shankar E and Gupta S. Chamomile:
A herbal medicine of the past with bright future. Mol.
Med. Rep. (2010) 3: 895.
McKay DL and Blumberg JB. A review of the
bioactivity and potential health benefits of Chamomile
Tea (Matricaria recutita L.). Phytother. Res. (2006)
20: 519–30
Petronilho S, Maraschin M, Coimbra MA and Rocha
SM. In vitro and in vivo studies of natural products:
A challenge for their valuation. The case study of
chamomile (Matricaria recutita L.). Ind. Crops
Prod. (2012) 40: 1-12.
Cvetanović A, Švarc-Gajić J, Zeković Z, Savić S, Vulić
J, Mašković P and Ćetković G. Comparative analysis
of antioxidant, antimicrobiological and cytotoxic
activities of native and fermented chamomile ligulate
flower extracts. Planta (2015) 242: 721-32.
Srivastava JK, Pandey M and Gupta S. Chamomile,
a novel and selective COX-2 inhibitor with antiinflammatory activity. Life Sci. (2009) 85: 663-9.
Srivastava JK and Gupta S. Antiproliferative and
apoptotic effects of chamomile extract in various
human cancer cells. J. Agric. Food Chem. (2007) 55:
9470-8.
Kassi E, Papoutsi Z, Fokialakis N, Messari I, Mitakou
S and Moutsatsou P. Greek plant extracts exhibit
selective estrogen receptor modulator (SERM)-like
properties. J. Agric. Food Chem. (2004) 52: 6956-61.
Rafraf M, Zemestani M and Asghari-Jafarabadi M.
Effectiveness of chamomile tea on glycemic control
and serum lipid profile in patients with type 2 diabetes.
J. Endocrinol. Invest. (2015) 38: 163-70.
Zand RSR, Jenkins DJ and Diamandis EP. Effects
of natural products and nutraceuticals on steroid
hormone-regulated gene expression. Clin. Chim. Acta
(2001) 312: 213-9.
Avallone R, Zanoli P, Puia G, Kleinschnitz M, Schreier
P and Baraldi M. Pharmacological profile of apeignin,
a flavonoid isolated from Matricaria chamomilla.
Biochem. Pharmacol. (2000) 59: 1387-94.
Viola H, Wasowski C, De Stein ML, Wolfman
C, Silveira R, Dajas F, Medina J and Paladini A.
Apigenin, a component of Matricaria recutita flowers,
is a central benzodiazepine receptors-ligand with
anxiolytic effects. Planta Med. (1995) 61: 213-6.
Nakazawa T, Yasuda T, Ueda J and Ohsawa K.
Antidepressant-like effects of apigenin and 2, 4,
5-trimethoxycinnamic acid from Perilla frutescens in
the forced swimming test. Biol. Pharm. Bull. (2003)
26: 474-80.
Sharifi F, Simbar M, Mojab F and Majd HA.
Comparison of the effects of Matricaria chamomila
(Chamomile) extract and mefenamic acid on the
intensity of premenstrual syndrome. Complement.
Ther. Clin. Pract. (2014) 20: 81-8.
Sharifi F, Simbar M, Mojab F and Alavi Majd H.
Comparison of the Effects of Matricaria chamomila
(Chamomile) Extract and Mefenamic Acid on the
Intensity of Mastalgia Associated With Premenstrual
Syndrome. Women›s Health Bull. (2014) 1: e20042.
Zargaran A, Borhani-Haghighi A, Faridi P,
Daneshamouz S, Kordafshari G and Mohagheghzadeh
A. Potential effect and mechanism of action of
topical chamomile (Matricaria chammomila L.) oil
on migraine headache: A medical hypothesis. Med.
Hypotheses (2014) 83: 566-9.
Abu Bakr Muhammad Ibn Zakariya Al Razi. Al Havi
[Liber Continent] Vol. 3. Muhammad Muhammad
Esmail (ed.) Dar al- kotob Al- Ilmiyah Publishers,
Beirut, Lebanon (2000) 7.
Aghili Khorasani Shirazi SMH. Makhzan al-Advyh.
1nd ed. Bavardaran Publisher, Tehran (2001) 194-193.
Jabbari M, Hashempur MH, Razavi SZE, Shahraki
HR, Kamalinejad M and Emtiazy M. Efficacy and
short-term safety of topical Dwarf Elder (Sambucus
ebulus L.) versus diclofenac for knee osteoarthritis:
A randomized, double-blind, active-controlled trial. J.
Ethnopharmacol. (2016) 188: 80-6.
Baba SA and Malik SA. Determination of total
phenolic and flavonoid content, antimicrobial and
antioxidant activity of a root extract of Arisaema
jacquemontii Blume. J. Taibah. Univ. Sci. (2015) 9:
449-54.
Mulinacci N, Romani A, Pinelli P, Vincieri F and
Prucher D. Characterization of Matricaria recutita
L. Flower extracts by HPLC-MS and HPLC-DAD
analysis. Chromatographia (2000) 51: 301-7.
Herb-Drug Interactions: German Chamomile.
Medicinal Plants. [serial online] 2011 [cited 2017 may
21]. Available from: URL: http://medicinalplants.us/
herb-drug-interactions-german-chamomile.
Huang W-Y, Cai Y-Z and Zhang Y. Natural phenolic
compounds from medicinal herbs and dietary plants:
potential use for cancer prevention. Nutr. Cancer
(2009) 62: 1-20.
Shukla S and Gupta S. Apigenin: a promising molecule
for cancer prevention. Pharm. Res. (2010) 27: 962-78.
(15)
(16)
(17)
(18)
(19)
(20)
(21)
(22)
(23)
(24)
(25)
(26)
(27)
(28)
(29)
(30)
(31)
(32)
(33)
(34)
(35)
(36)
(37)
(38)
(39)
(40)
(41)
Effects of chamomile syrup in reducing prolactin
1621
Pourabbas R and Delazar A. The effect of German
chamomile mouthwash on dental plaque and gingival
inflammation. Iran. J. Pharm. Res. (2010) 105-9.
Kempuraj D, Tagen M, Iliopoulou B, Clemons
A, Vasiadi M, Boucher W, House M, Wolfberg A
and Theoharides T. Luteolin inhibits myelin basic
protein‐induced human mast cell activation and mast
cell‐dependent stimulation of Jurkat T cells. Br. J.
Pharmacol. (2008) 155: 1076-84.
Kumar S, Mansel R, Scanlon M, Hughes L, Edwards
CA, Woodhead J and Newcombe R. Altered
responses of prolactin, luteinizing hormone and
follicle stimulating hormone secretion to thyrotrophin
releasing hormone/gonadotrophin releasing hormone
stimulation in cyclical mastalgia. Br. J.Surg. (1984)
71: 870-3.
Mansel R and Dogliotti L. European multicentre trial
of bromocriptine in cyclical mastalgia. Lancet (1990)
335: 190-3.
Wuttke W, Jarry H, Christoffel V, Spengler B and
Seidlova-Wuttke D. Chaste tree (Vitex agnus-castus)–
pharmacology and clinical indications. Phytomedicine
(42)
(43)
(44)
(45)
(46)
(2003) 10: 348-57.
van Die MD, Burger HG, Teede HJ and Bone KM.
Vitex agnus-castus extracts for female reproductive
disorders: a systematic review of clinical trials. Planta
Med. (2013) 79: 562-75.
Kilicdag E, Tarim E, Bagis T, Erkanli S, Aslan E,
Ozsahin K and Kuscu E. Fructus agni casti and
bromocriptine for treatment of hyperprolactinemia and
mastalgia. Int. J. Gynaecol. Obstet. (2004) 85: 292-3.
Jarry H, Leonhardt S, Gorkow C and Wuttke W.
In vitro prolactin but not LH and FSH release is
inhibited by compounds in extracts of Agnus castus:
direct evidence for a dopaminergic principle by the
dopamine receptor assay. Exp. Clin. Endocrinol.
(1994) 102: 448-54.
Verhelst J, Abs R, Maiter D, van den Bruel A,
Vandeweghe M, Velkeniers B, Mockel J, Lamberigts
G, Petrossians P and Coremans P. Cabergoline in
the treatment of hyperprolactinemia: a study in 455
patients. J. Clin. Endocrinol. Metab. (1999) 84: 2518-
22
)